Afatinib for EGFR, HER2 or HER3 mutated solid tumors: A phase II Belgian precision study
Background: The Belgian Precision initiative aims to implement tumor-agnostic NGS in advanced cancer patients (pts) and enhance access to genotype-matching drugs. The current study aimed to investigate the efficacy of afatinib in advanced pre-treated solid cancers with an EGFR (excluding non-small cell lung cancer (NSCLC)), HER2 or HER3 mutation. ; Kom op tegen kanker
| Verfasser: | |
|---|---|
| Dokumenttyp: | Artikel |
| Erscheinungsdatum: | 2023 |
| Verlag/Hrsg.: |
ELSEVIER
|
| Schlagwörter: | Interests / Personal / Full or part-time Employment: CDR-Life / Other / Project Lead: CDR-Life L Borras: Financial Interests / Financial Interests / Leadership Role: CDR-Life / Stocks/Shares: CDR-Life S Biswas: Financial Interests / Full or part-time Employment: CDR-Life R Leidner: Financial Interests / Advisory Role: Bristol Myers Squibb / Project Lead: Bristol Myers Squibb / Incycte E Calvo: Financial Interests / Advisory Board: Adcendo / Amunix / Anaveon / AstraZeneca / BMS / Janssen / MonTa / MSD / Nanobiotix / Nouscom / Novartis / Servier / Tar- gImmune / T-knife / Chugai / Elevation Oncology / Ellipses Pharmacy / SyneosHealth / Genmab / Diac- curate / Invited Speaker: OncoDNA / PharmaMar / Roche/Genentech |
| Sprache: | unknown |
| Permalink: | https://search.fid-benelux.de/Record/base-28879512 |
| Datenquelle: | BASE; Originalkatalog |
| Powered By: | BASE |
| Link(s) : | http://hdl.handle.net/1942/41937 |
